Abgenix Inc (1052837) SEC Filing 10-Q Quarterly report for the period ending Friday, September 30, 2005

Abgenix Inc

CIK: 1052837

Exhibit 99.1








Greg Mann




Corporate Communications & Investor Relations


(510) 284-6566


Abgenix Announces Third Quarter 2005 Financial Results


FREMONT, Calif. - October 25, 2005 - Abgenix, Inc. (NASDAQ: ABGX) today announced financial results for the third quarter ended September 30, 2005.  The company reported a net loss of $36.8 million, or $0.41 per share, for the third quarter of 2005, compared to $42.4 million, or $0.48 per share, for the same period in 2004.


Net cash used in operating activities in the third quarter of 2005 was $21.8 million, compared to $36.5 million in the third quarter of 2004.  During the quarter, the company repurchased approximately $13.8 million of its outstanding convertible notes due in 2007, and ended the third quarter of 2005 with $343.6 million in cash, cash equivalents and marketable securities. 


“We continue to execute on our goals for 2005, including progress with our partner, Amgen, towards the initiation of our regulatory filing to the FDA for panitumumab before year-end 2005,” said Bill Ringo, president and chief executive officer of Abgenix.  “Our third quarter performance reflects expense reductions realized from our recently announced restructuring and facility consolidation, efforts to expand our product portfolio, and investment in the development and potential commercialization of panitumumab.”


Revenues for the third quarter of 2005 were $4.7 million compared to $3.1 million for the same period in 2004.  Revenues for the third quarter of 2005 consisted primarily of contract revenues from technology licensing agreements and included licensing revenues and an IND-related milestone from our partner Agensys.  For the third quarter of 2004, revenues included a milestone payment from Amgen for advancement of denosumab (AMG-162), a XenoMouse®-derived antibody, into pivotal clinical trials for bone loss.  The company’s contract revenues generally vary from period to period based on the progress of research and development efforts by the company’s collaborators and licensees.




The following information was filed by Abgenix Inc on Tuesday, October 25, 2005 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Abgenix Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Abgenix Inc.


Assess how Abgenix Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Abgenix Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2005 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools
CIK: 1052837
Form Type: 10-Q Quarterly Report
Accession Number: 0001104659-05-053933
Submitted to the SEC: Wed Nov 09 2005 1:34:48 PM EST
Accepted by the SEC: Wed Nov 09 2005
Period: Friday, September 30, 2005
Industry: Biological Products No Disgnostic Substances

External Resources:

Bookmark the Permalink: